OBJECTIVES:  The aim was to determine the consumption of resources at all three levels of risk patients (Mild (L), Moderate (M) and Severe (S)) and the economic impact of the specialized management of patients in each insurer. METHODS:  To collect and analyze the costs of care and medicines for patients with hemophilia A in Colombia the registration system information Colombian Fund High-Cost Diseases, which has 64 variables from 2015 to follow up was used risk management in 48 insurers. RESULTS:  A measurement of the costs generated in the report of February 1, 2014 to January 31, 2015. 45 insurers join 1.436 (94 %) haemophilia type A (from 1.525 reported) were identified. They are L: 21.2%, M: 32.6%, S: 41.7%. (Unknown: 4.6%). The range of enrollment of patients by insurer was between a minimum: 1, maximum: 238. The average cost of care ( drug ) is US $ 85.305,54. It was identified that the average care accounted for 10% of the costs of insurance and in relation to drugs , which were included in care plans are: 84% (Factor VIII) and those whose were outise any care plan represented 6%. CONCLUSIONS:  It is clear that management costs hemophiliacs are attributed mostly to prophylaxis and management of bleeding. The range of membership significantly affects an extrapolation of the results by the insurer. This study identifies efficient options in the treatment of hemophilia for possible future risk adjustments.